Dynamic Drug Development

Psychedelic healthcare is no longer a pipe dream, with several compounds demonstrating safety and efficacy in patient populations. As treatments progress through clinical trials, drug developers, regulators and healthcare providers are working closely to facilitate their integration into existing medical frameworks. This includes the investigation of proprietary shorter acting tryptamines and novel drug delivery technologies. But which psychedelic medicines will lead the industry into its next phase of evolution? We speak to a panel of industry leading CEO's to discuss their pioneering work, and explore new ideas.